Dr. John Sondek, Chief Scientific Officer, Board member

Dr. Sondek received his PhD in Biochemistry from Johns Hopkins University in 1992. Upon completing postdoctoral studies at Yale University in 1996 as a Damon-Runyon-Walter Winchell Fellow, he joined the University of North Carolina-Chapel Hill, was name a Pew Scholar in the Biomedical Sciences, and is now a Professor in the Departments of Pharmacology, and Biochemistry & Biophysics as well as a member of the Lineberger Comprehensive Cancer Center.
His independent research program has been continuously funded since its inception from various agencies including the National Institutes of Health, GlaxoSmithKline and the American Cancer Society. His research is focused on understanding protein complexes involved in signal transduction cascades as potential targets for new therapeutics against cancer and neurological diseases. He has authored or co-authored over 80 original research articles and holds five patents related to the mutagenesis and screening of proteins.